RGD Reference Report - FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia.

Authors: Lin, TS  Flinn, IW  Modali, R  Lehman, TA  Webb, J  Waymer, S  Moran, ME  Lucas, MS  Farag, SS  Byrd, JC 
Citation: Lin TS, etal., Blood. 2005 Jan 1;105(1):289-91. Epub 2004 Jun 24.
RGD ID: 11344968
Pubmed: PMID:15217834   (View Abstract at PubMed)
DOI: DOI:10.1182/blood-2004-02-0651   (Journal Full-text)

The in vivo mechanism of action of alemtuzumab (anti-CD52; Campath-1H) remains unclear. With rituximab, FCGR3A and FCGR2A high-affinity polymorphisms have been associated with clinical response in lymphoma but not in CLL, suggesting potential divergent mechanisms of action between these 2 diseases. Herein, we examined FCGR3A (V/V, n = 4; V/F, n = 10; F/F, n = 19) and FCGR2A (A/A, n = 5; H/A, n = 22; H/H, n = 6) polymorphisms in 36 patients with relapsed CLL who were treated with thrice-weekly alemtuzumab for 12 weeks to assess the potential influence these high-affinity FcgammaR receptor polymorphisms had on response to alemtuzumab. Response to alemtuzumab was similar regardless of FCGR3A polymorphism (V/V, 25%; V/F, 40%; F/F, 32%) or FCGR2A polymorphism (A/A, 40%; H/A, 32%; H/H, 33%). These findings indicate that FCGR3A and FCGR2A polymorphisms may not predict response to alemtuzumab in CLL. Future studies examining larger cohorts of alemtuzumab-treated patients with CLL will be required to definitively determine the predictive value of specific FCGR polymorphisms to treatment response.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
FCGR2AHumanlymphoid leukemia no_associationIAGP DNA:polymorphism:exon:p.H131A (human)RGD 
FCGR3AHumanlymphoid leukemia no_associationIAGP DNA:polymorphism:exon:p.F158V (rs396991) (human)RGD 
Fcgr2aRatlymphoid leukemia no_associationISOFCGR2A (Homo sapiens)DNA:polymorphism:exon:p.H131A (human)RGD 
Fcgr3Mouselymphoid leukemia no_associationISOFCGR2A (Homo sapiens)DNA:polymorphism:exon:p.H131A (human)RGD 
Fcgr3aRatlymphoid leukemia no_associationISOFCGR3A (Homo sapiens)DNA:polymorphism:exon:p.F158V (rs396991) (human)RGD 
Fcgr4Mouselymphoid leukemia no_associationISOFCGR3A (Homo sapiens)DNA:polymorphism:exon:p.F158V (rs396991) (human)RGD 

Objects Annotated

Genes (Rattus norvegicus)
Fcgr2a  (Fc gamma receptor 2A)
Fcgr3a  (Fc gamma receptor 3A)

Genes (Mus musculus)
Fcgr3  (Fc receptor, IgG, low affinity III)
Fcgr4  (Fc receptor, IgG, low affinity IV)

Genes (Homo sapiens)
FCGR2A  (Fc gamma receptor IIa)
FCGR3A  (Fc gamma receptor IIIa)


Additional Information